News

People may not be fully aware of added cost exposures if they shift to bronze Affordable Care (ACA) plans, says Margaret A. Murray, M.P.A., CEO of the Association for Community Health Plans. Murray says the nonnetwork plans that the Trump administration is promoting will result in underinsurance.

Gilead's Bixlenvo, the smallest once-daily HIV pill yet, has been approved by the FDA for virologically suppressed adults on complex regimens.

University of Maryland researchers used machine learning models trained on claims data of adults with diabetes to predict monthly risk of nine acute and chronic complications.

Brepocitinib, now with the brand name Lisraya, treats adults with dermatomyositis, rare autoimmune disease. It is available now, but Priovant Therapeutics has not provided a list price.

Eli Lilly’s Zepbound real-world study shows older adults with obesity cut non-drug healthcare costs 25% via fewer hospital and ER visits, informing Medicare coverage.

In a wide-ranging interview, the CEO of the Association for Community Affiliated Plans (ACAP) discusses Medicaid enrollment, Medicaid work requirements, the ACA marketplace plan, her 25 years at the helm of ACAP and whether she is burnt out.

Margaret A. Murray, M.P.A., CEO of the Association for Community Affiliated Plans, says outreach and texting will be key to keeping eligible Medicaid enrollees covered under new redetermination and work requirements.

A phase 3 trial of intravenous arginine was stopped early after it did not meaningfully shorten acute pain sickle cell crises' recovery time.

A new study from UCLA has found that insurers saw $3,820 lower monthly costs from the use of biosimilars. Cancer patients saved $39.50 in monthly out-of-pocket costs.

A pilot combining AI screening with structured nodule follow-up found early lung cancer in 1.6% of flagged patients.

The FDA approved ViiV Healthcare's Tivicay PD for children weighing at least 2 kg, making it the first second-generation HIV integrase inhibitor for this group.

Tevimbra plus Ziihera with chemo raises survival in first-line HER2-positive gastroesophageal cancer, offering a new FDA-approved option.

Rasonque (daraxonrasib) was approved more than six months ahead of its PDUFA date. It has a wholesale acquisition cost of $39,800 for a 30-day supply.

How the USPS financial crisis changes the conversation about healthcare communication and mailing.

Stem cell transplants from younger, more mismatched unrelated donors showed favorable one-year outcomes in a new ACCESS trial analysis.

Over three years, Advocate Health Care is investing $1 billion in health and wellness initiatives in Chicago, including building a new hospital, expanded outpatient services and new workforce development initiatives.

Aon projects a fourth straight year of near double-digit health cost growth for U.S. employers, with 2027 costs set to top $19,000 per worker.

The subcutaneous version of Leqembi has a wholesale acquisition cost of $770 weekly.

Oregon Health & Science University researchers found sensitive caregiving in infancy can offset ADHD risk linked to higher maternal inflammation in pregnancy, a new study shows.

Some dermatologists are calling for the switch because resistance to antifungal medications is growing.

A deficiency in the hormone GDF15 correlates with liver damage biomarkers, suggesting the hormone may protect against MASH progression and offer a new therapeutic target.

HIV medication adherence rose after SNAP payments and fell nearly 12 points by the end of the benefit cycle, according to a new study of Philadelphia SNAP beneficiaries.

Genglycos is a one-time infusion to replace the G6PC gene in patients with glycogen storage disease type Ia, a rare genetic disorder. It will have a wholesale acquisition cost of $2.7 million per patient.

Pasatru is approved to treat adults with fibrodysplasia ossificans progressiva (FOP). It will have an annual list pricing range at launch of $693,000 to $2.1 million, depending on dose and patient weight.

Medicaid expansion was linked to improved insurance coverage, earlier diagnosis, and better survival for NSCLC patients, especially in underserved areas.

Cleveland Clinic and Siemens Healthineers signed a 10-year deal to expand imaging, cancer care and staff training.

The results of an Australian mouse-model-based study show that the bladder nerves that detect urinary tract infections may drive the urinary urgency that helps clear infection.

A Brukinsa access program for CLL patients in low- and middle-income countries has been extended through 2028, aiming to reach about 1,000 patients.